Simulating Target Trials of Postexposure Vaccination Using Observational Data

Overview

Postexposure vaccination offers a promising strategy to prevent or modify disease after pathogen exposure, but conducting randomized trials is challenging. This article defines target trials for postexposure vaccination and demonstrates how observational data can emulate these trials, emphasizing the critical role of incubation periods and vaccination timing.

Background

Vaccination traditionally focuses on preventing disease before exposure, while postexposure vaccination remains underutilized despite its potential to curb outbreaks. Conducting randomized postexposure vaccine trials is difficult due to the narrow window between exposure and symptom onset and ethical considerations. Observational data, such as electronic health records and contact tracing databases, can be used to emulate target trials to estimate vaccine effectiveness. The approach helps clarify causal questions and addresses biases inherent in observational analyses.

Data Highlights

The article discusses the importance of aligning time zero, eligibility, and treatment assignment in observational data to emulate randomized trials. It highlights the necessity of specifying vaccination timing windows relative to exposure and symptom onset to accurately estimate vaccine effectiveness. Simulation studies illustrate benefits of the target trial framework, though specific numerical data are not provided in the abstract.

Key Findings

• Postexposure vaccination effectiveness depends critically on the timing of vaccine administration relative to pathogen incubation periods.
• Randomized postexposure vaccine trials are logistically challenging and sometimes unethical, limiting their feasibility.
• Observational data can be used to emulate target trials by carefully defining eligibility, treatment strategies, and timing to reduce biases such as immortal time bias.
• Aligning time zero (start of follow-up), eligibility criteria, and treatment assignment is essential to validly estimate vaccine effectiveness from observational data.
• An example protocol for postexposure vaccination against mpox demonstrates practical application of the target trial emulation approach.
• Simulation studies show that the target trial framework can clarify causal questions and improve the validity of observational vaccine effectiveness estimates.

Clinical Implications

Clinicians and public health practitioners should recognize the potential of postexposure vaccination to mitigate disease if administered promptly after exposure. When randomized trials are infeasible, carefully designed observational studies emulating target trials can provide valuable evidence on vaccine effectiveness and optimal timing. Understanding the incubation period and ensuring rapid vaccination are critical to maximizing postexposure vaccine benefits.

Conclusion

Emulating target trials using observational data offers a practical and rigorous approach to evaluate postexposure vaccine effectiveness, especially when randomized trials are not possible. This framework helps address biases and clarifies causal interpretations, ultimately supporting better-informed vaccination strategies.

References

1. Hernán MA, Robins JM 2016 -- Using Big Data to Emulate a Target Trial When a Randomized Trial Is Not Available
2. CDC 2022 -- Mpox (Monkeypox) Vaccination Guidance